Single-patient trials determine statin tolerability

Single-patient trials determine statin tolerability

(HealthDay)—In patients with statin-related myalgia, single-patient randomized trials of statin and placebo can determine whether the myalgia is actually due to the statin, according to a small study published in the March 4 issue of the Annals of Internal Medicine.

Tisha R. Joy, M.D., from Western University in London, Canada, and colleagues conducted n-of-1 trials in eight patients with statin-related myalgia. Patients were randomly assigned to statin or placebo for up to three weeks, with three-week washout intervals.

The researchers found that for each patient there were no significant differences between statin or placebo in terms of visual analog scale myalgia score, symptom-specific visual analog scale score, pain interference score, and pain severity score. Five patients resumed , reducing their low-density lipoprotein cholesterol after a median of 10 months of follow-up.

"In selected patients with a history of statin-related myalgia whose symptoms are difficult to evaluate, n-of-1 trials may be a useful method for determining statin tolerability," Joy and colleagues conclude.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Towards renal artery stenosis treatment

18 hours ago

Renal artery stenting to open blockages in the kidney arteries may benefit patients who have historically been excluded from modern clinical trials, according to new recommendations for renal artery stenosis e-published in ...

New technologies help people with heart disease

23 hours ago

People taking part in cardiac rehabilitation exercise programmes are likely to maintain healthy behaviours for longer with text message and web-based support, according to recent research from the University of Auckland.

A novel pathway for prevention of heart attack and stroke

Aug 21, 2014

A recent Finnish study could pave the way for preventing brain and cardiac ischemia induced by atherosclerosis. Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which ...

User comments